Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
The Company also announces completion of enrollment in 12-week, Phase 1b trial of pemvidutide in subjects with non-alcoholic fatty liver disease (NAFLD) GAITHERSBURG, Md., April 01, 2022 (GLOBE ...
In my last note on Altimmune, Inc. (ALT) shared in late August, I made the bull case for its stock. I discussed the Gaithersburg, Maryland based biotech's lead and only drug candidate, pemvidutide, ...
BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that its collaborator, ...
A multicenter team including Endeavor Health and Eli Lilly found that once-weekly eloralintide produced dose-dependent weight loss up to 20% over 48 weeks in adults with obesity or overweight without ...
Pooled 48-week results from two Phase II studies show sustained antiviral responses and a favorable safety profile of AHB-137 in HBeAg-negative chronic hepatitis B patients on NA therapy. The ...
Lee Roth - Burns McClellan, Inc. Thanks, operator. As a reminder, a press release summarizing the results of the trial can be found on the Investor Relations section of the company's website. This ...
Johnson & Johnson announced new 48-week data from the Phase 3 ASTRO study evaluating TREMFYA subcutaneous induction and maintenance therapy in adults with moderately to severely active ulcerative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results